About Gilead Sciences Inc.
Gilead Sciences is an American biopharmaceutical company that discovers, develops, and commercializes medicines, mainly antiviral drugs for HIV/AIDS, viral hepatitis, and other serious diseases. Michael L. Riordan founded the company in 1987 in Foster City, California. Gilead trades on the Nasdaq under the ticker symbol GILD and is a component of the Nasdaq-100, S&P 100, and S&P 500. Its HIV portfolio includes Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo, among others. In liver disease and virology, key products are Epclusa for hepatitis C, Vemlidy for hepatitis B, Livdelzi, and the COVID-19 antiviral Veklury (remdesivir). Gilead also sells CAR T-cell therapies Yescarta and Tecartus, and Trodelvy, an antibody-drug conjugate used in cancer treatment.
No recent coverage for this asset.
A sourced map of Gilead Sciences Inc.'s relationships is on the way.
Partners, competitors and related assets, each link independently verified and source-linked before it appears here.
The Crypto Briefing podcast is on the way.
Conversations on Gilead Sciences Inc. and the wider market, hosted by our team, will appear here once episodes are live.